Instil Bio, Inc. (TIL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50K 100K 150K Q4 '20: 138K Q1 '21: 94K Q2 '21: 52K Q3 '21: 0 Q4 '21: 0 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -119.3M Q4 '21: -155.6M Q1 '22: -186.4M Q2 '22: -209.8M Q3 '22: -223.4M Q4 '22: -226.5M Q1 '23: -230.6M Q2 '23: -192.9M Q3 '23: -202.9M Q4 '23: -159.2M Q1 '24: -124.7M Q2 '24: -117.8M Q3 '24: -74.7M Q4 '24: -73.5M Q1 '25: -80.1M Q2 '25: -89.5M Q3 '25: -80.8M Q4 '25: -78.6M Q1 '26: -55M Q2 '26: -37.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -118.6M Q4 '21: -156.8M Q1 '22: -187.8M Q2 '22: -211.5M Q3 '22: -224.7M Q4 '22: -223.2M Q1 '23: -226.1M Q2 '23: -185.8M Q3 '23: -197M Q4 '23: -156.1M Q1 '24: -123.3M Q2 '24: -119.6M Q3 '24: -75.2M Q4 '24: -74.1M Q1 '25: -78M Q2 '25: -84.5M Q3 '25: -75.1M Q4 '25: -71.4M Q1 '26: -47.4M Q2 '26: -30.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -96.2M Q4 '21: -122.1M Q1 '22: -159.5M Q2 '22: -174.5M Q3 '22: -186M Q4 '22: -180.2M Q1 '23: -159.8M Q2 '23: -132.1M Q3 '23: -105.6M Q4 '23: -82M Q1 '24: -61.8M Q2 '24: -52.8M Q3 '24: -58.5M Q4 '24: -55.7M Q1 '25: -45.5M Q2 '25: -49.7M Q3 '25: -40.1M Q4 '25: -36.6M Q1 '26: -33.8M Q2 '26: -23.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '20: -80.4M Q1 '21: -104M Q2 '21: -141.2M Q3 '21: -180.8M Q4 '21: -180M Q1 '22: -228.4M Q2 '22: -261.1M Q3 '22: -276M Q4 '22: -264.8M Q1 '23: -232.6M Q2 '23: -185.7M Q3 '23: -139.2M Q4 '23: -102.7M Q1 '24: -74M Q2 '24: -58M Q3 '24: -58.6M Q4 '24: -55.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 13M Q2 '20: 16.8M Q3 '20: 16.9M Q1 '21: 35M Q2 '21: 128.7M Q3 '21: 128.8M Q1 '22: 129.1M Q2 '22: 129.4M Q3 '22: 129.7M Q1 '23: 6.5M Q2 '23: 6.5M Q3 '23: 6.5M Q1 '24: 6.5M Q2 '24: 6.5M Q3 '24: 6.5M Q1 '25: 6.5M Q2 '25: 6.6M Q3 '25: 6.8M Q1 '26: 6.8M Q2 '26: 6.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '21: -2.30 Q4 '21: -1.71 Q1 '22: -1.47 Q2 '22: -1.66 Q3 '22: -1.76 Q4 '22: -34.46 Q1 '23: -42.81 Q2 '23: -45.22 Q3 '23: -55.16 Q4 '23: -24.00 Q1 '24: -18.97 Q2 '24: -18.39 Q3 '24: -11.56 Q4 '24: -11.39 Q1 '25: -11.97 Q2 '25: -12.92 Q3 '25: -11.39 Q4 '25: -10.74 Q1 '26: -7.04 Q2 '26: -4.43 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.